FRED P. ROSENFELT, M.D.
To the editor: Harker and colleagues (1) recently reported their results with second-line therapy of Hodgkin's disease resistant to treatment with mechlorethamine, vincristine, procarbazine, and prednisone (MOPP). Their retrospective review failed to show significant differences in response rates or survival for patients treated with either doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) or bleomycin, lomustine, doxorubicin, and vinblastine (B-CAVe). The authors conclude that the 20% 5-year survival rate of their patients supports the need for new treatment approaches.
Harker and colleagues failed to comment, however, on the fact that these two treatment protocols contain three of the same drugs (doxorubicin, bleomycin,
ROSENFELT FP. Combination Chemotherapy for Hodgkin's Disease. Ann Intern Med. ;102:554–555. doi: 10.7326/0003-4819-102-4-554_2
Download citation file:
Published: Ann Intern Med. 1985;102(4):554-555.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use